Radiation Oncology | Christopher J. Schultz, MD | Chair and Professor

Christopher J. Schultz, MD, FACR, FASTRO

Chair and Bernard & Miriam Peck Family Professor of Radiation Oncology

Locations

Radiation Oncology

Contact Information

(414) 805-4472

Biography

Training

Residency Radiation Oncology, University of Wisconsin Hospitals and Clinics, Madison, WI (1989-1990)

Residency Radiation Oncology, Presbyterian Hospital, New York, NY (1986-1988)

Internship Children's Mercy Hospital, Kansas City, MO (1985-1986)

Certifications

Recertification, Radiation Oncology, American Board of Radiology (2000)

Board Certification, Radiation Oncology, American Board of Radiology (1990)

Patient Care Emphases

Head and neck cancer
Hodgkin's Disease
Low dose rate irradiation
Gamma Knife stereotactic radiosurgery
Lymphoma
Brain tumors

View Provider Profile

Education

1985, Medical College of Wisconsin, MD

Salvage of Recurrence after Surgery and Adjuvant Therapy: A Multi-institutional Study.

(Zenga J, Graboyes E, Janz T, Drake V, Rettig E, Desai S, Nickel C, Shabani S, Padhya T, Scarpinato M, Stadler M, Massey B, Campbell B, Shukla M, Awan M, Schultz CJ, Wong S, Jackson RS, Pipkorn P.) Otolaryngol Head Neck Surg. 2019 Feb 12:194599819830664.
Phase 2 Study of Radiation Therapy Plus Low Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420.

(Lieberman FS, Wang M, Robins HI, Tsien CI, Curran WJ Jr, Werner-Wasik M, Smith RP, Schultz C, Hartford AC, Zhang P, Mehta MP.) Int J Radiat Oncol Biol Phys. 2018 Nov 26.
Consolidative Whole-Brain Radiation Therapy Versus Autologous Stem Cell Transplant for Primary Central Nervous System Lymphoma: A Large Dose of Perspective and Perhaps a Lower Dose of Radiation Are in Order.

(Bovi JA, Schultz CJ, Mehta MP, Corn BW.) Int J Radiat Oncol Biol Phys. 2018 Sep 01;102(1):59-60.
Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial.

(Bell EH, Zhang P, Fisher BJ, Macdonald DR, McElroy JP, Lesser GJ, Fleming J, Chakraborty AR, Liu Z, Becker AP, Fabian D, Aldape KD, Ashby LS, Werner-Wasik M, Walker EM, Bahary JP, Kwok Y, Yu HM, Laack NN, Schultz CJ, Gray HJ, Robins HI, Mehta MP, Chakravarti A.) JAMA Oncol. 2018 Oct 01;4(10):1405-1409.
Early Prediction of Acute Xerostomia During Radiation Therapy for Head and Neck Cancer Based on Texture Analysis of Daily CT.

(Wu H, Chen X, Yang X, Tao Y, Xia Y, Deng X, Zheng C, Robbins J, Schultz C, Li XA.) Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1308-1318.
Current Predictive Indices and Nomograms To Enable Personalization of Radiation Therapy for Patients With Secondary Malignant Neoplasms of the Central Nervous System: A Review.

(Gilbride L, Siker M, Bovi J, Gore E, Schultz C, Hall WA.) Neurosurgery. 2018 May 01;82(5):595-603.
NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients.

(Ali AN, Zhang P, Yung WKA, Chen Y, Movsas B, Urtasun RC, Jones CU, Choi KN, Michalski JM, Fischbach AJ, Markoe AM, Schultz CJ, Penas-Prado M, Garg MK, Hartford AC, Kim HE, Won M, Curran WJ Jr.) J Neurooncol. 2018 Mar;137(1):39-47.
Precision Oncology and Genomically Guided Radiation Therapy: A Report From the American Society for Radiation Oncology/American Association of Physicists in Medicine/National Cancer Institute Precision Medicine Conference.

(Hall WA, Bergom C, Thompson RF, Baschnagel AM, Vijayakumar S, Willers H, Li XA, Schultz CJ, Wilson GD, West CML, Capala J, Coleman CN, Torres-Roca JF, Weidhaas J, Feng FY.) Int J Radiat Oncol Biol Phys. 2018 Jun 01;101(2):274-284.
R-IDEAL: A Framework for Systematic Clinical Evaluation of Technical Innovations in Radiation Oncology.

(Verkooijen HM, Kerkmeijer LGW, Fuller CD, Huddart R, Faivre-Finn C, Verheij M, Mook S, Sahgal A, Hall E, Schultz C.) Front Oncol. 2017;7:59.
Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813.

(Chang S, Zhang P, Cairncross JG, Gilbert MR, Bahary JP, Dolinskas CA, Chakravarti A, Aldape KD, Bell EH, Schiff D, Jaeckle K, Brown PD, Barger GR, Werner-Wasik M, Shih H, Brachman D, Penas-Prado M, Robins HI, Belanger K, Schultz C, Hunter G, Mehta M.) Neuro Oncol. 2017 02 01;19(2):252-258.
The MRI-Linear Accelerator Consortium: Evidence-Based Clinical Introduction of an Innovation in Radiation Oncology Connecting Researchers, Methodology, Data Collection, Quality Assurance, and Technical Development.

(Kerkmeijer LG, Fuller CD, Verkooijen HM, Verheij M, Choudhury A, Harrington KJ, Schultz C, Sahgal A, Frank SJ, Goldwein J, Brown KJ, Minsky BD, van Vulpen M, MR-Linac Consortium Clinical Steering Committee.) Front Oncol. 2016;6:215.
A Mutation and Prognostic Biomarker Study in Grade II and III Gliomas Utilizing a Combined Cohort of NRG Oncology/RTOG 9802 and 9813.

(Bell EH, McElroy JP, Fleming J, Timmers C, Chakraborty AR, Salavaggione AL, Chang SM, Shaw EG, Aldape K, Brachman D, Schultz CJ, Shih HA, Curtis M, Hunter GK, Murtha AD, Zhang P, Won M, Mehta MP, Chakravarti A.) Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2S):S91.

Christopher J. Schultz, MD